Use

KP1019 is active against primary cancers, whereas NAMI-A is active against metastasis, secondary tumours that have moved to other areas. The treatment of metastasis is currently an area where improvement is urgently needed.KP1019, trans-[tetrachloro-bis(1H-indazole)ruthenate(III)], was tested in phase I clinical trials as a possible treatment option against colon cancer. Administered doses ranged from 25 to 600 mg twice weekly, and no significant side effects were noticed. The synthesis of KP1019 also starts with RuCl3·3H20, which is dissolved in ethanolic HCl and reacted with an excess of indazole .